attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. Datopotamab deruxtecan is approved in Japan under the brand name ...

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-3939 is comprised of a humanized anti-TA-MUC1 antibody, attached to a number of topoisomerase I inhibitor payloads (an exatecan ...

Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-3939 is comprised of a humanized anti-TA-MUC1 antibody, attached to a number of topoisomerase I inhibitor payloads (an exatecan ...

including the use of an EGFR tyrosine kinase inhibitor," said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. "If approved, datopotamab deruxtecan could become the first TROP2 directed ...

Specifically, the novel Trop-2-directed antibody and topoisomerase inhibitor conjugate is indicated ... the efficacy and safety of datopotamab deruxtecan across multiple cancers, including NSCLC ...

DS-3939 is designed using Daiichi Sankyo’s proprietary DXd ADC technology, which employs a combination of tetrapeptide-based cleavable linkers and topoisomerase I inhibitor payloads to deliver ...